|Bid||0.00 x 1000|
|Ask||0.00 x 2200|
|Day's Range||1.80 - 1.92|
|52 Week Range||0.69 - 2.65|
|Beta (3Y Monthly)||-1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 13, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.33|
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced receiving Notices of Allowance from IP Australia and the Japan Patent Office (JPO) related to methods of treating depression with AV-101, VistaGen’s oral NMDA (N-methyl-D-aspartate) receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder (MDD). “These patents, when issued, will extend our commercial protection of AV-101 into Australia and Japan, two additional major pharmaceutical markets,” stated Shawn Singh, Chief Executive Officer of VistaGen.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2018 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for.
Small VistaGen is building a portfolio of drugs aimed at depression and other mental health conditions, while giant Gilead gets a lower effective tax rate — all that and more in our Health Care Digest.
VistaGen Therapeutics Inc (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that the Company has exercised its option to acquire from Pherin Pharmaceuticals, Inc. (Pherin) the exclusive license for worldwide rights to develop and commercialize PH10, a first-in-class, intranasally administered neuroactive steroid (a “pherine”), with rapid-onset antidepressant effects for treatment of major depressive disorder (MDD) demonstrated in a phase 2a study. The Company secured the option for PH10 concurrently with its previously announced license agreement with Pherin for worldwide rights to develop and commercialize PH94B, also a first-in-class neuroactive pherine, which VistaGen is preparing for pivotal Phase 3 development as a nasal spray for acute on-demand treatment of social anxiety disorder (SAD).
VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that Shawn Singh, Chief Executive Officer of VistaGen, will present at the Credit Suisse 27th Annual Healthcare Conference to be held at The Phoenician in Scottsdale, Arizona on Wednesday, November 14, 2018 at 2:15 p.m. MST / 4:15 p.m. EST. A live audio webcast will be accessible at the time of the presentation on the investor page of VistaGen's website at ir.vistagen.com. A replay of the webcast will be archived on VistaGen's website following the conference.
VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced the appointment of Michael Liebowitz, M.D. to the Company’s CNS Clinical and Regulatory Advisory Board in preparation for pivotal Phase 3 development of PH94B as the first rapid-acting, on-demand treatment for social anxiety disorder (SAD), a debilitating social phobia which affects as many as 15 million American adults. “We are extremely pleased to be working with Dr. Liebowitz to prepare for and advance PH94B through our pivotal Phase 3 program for SAD.
The rapidly growing sectors have been gobbling up workers and office space in San Mateo County. Now they are running into each other's growth ambitions
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Both Pain Therapeutics and VistaGen Therapeutics were two biotech stocks seeing big gains on Wednesday. While Pain Therapeutics had no news to explain a 200% ...
VistaGen Therapeutics Inc.'s stock surged 13% in premarket trade Wednesday, after the company said it has been awarded U.S. Food and Drug Administration Fast Track Designation for a non-opioid pain treatment. The FDA has granted the designation, which aims to expedite the review of drugs for diseases with high unmet needs, to VistaGen's AV-101 small molecule NMDA (N-methyl-D-aspartate) receptor glycine B antagonist, which aims to treat neuropathic pain without causing sedation. Drug companies are racing to create a non-opioid pain treatment, given the current crisis affecting many communities with high numbers of opioid overdoses and deaths. VistaGen hares have gained 37% in 2018, while the S&P 500 has gained 9%.
Designation highlights serious unmet need for new treatment options for patients suffering from neuropathic pain Second FDA Fast Track designation for AV-101 since December.
VistaGen Therapeutics, Inc. (VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, and Pherin Pharmaceuticals, Inc., a biopharmaceutical company focused on development of novel treatments for neuropsychiatric and neuroendocrine conditions, today announced the signing of a license agreement granting VistaGen exclusive worldwide rights to develop and commercialize PH94B nasal spray, a Phase 3-ready drug candidate for as-needed (PRN) treatment of Social Anxiety Disorder (SAD). “SAD affects nearly 15 million Americans.
NEW YORK , Sept. 6, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
LONDON, UK / ACCESSWIRE / June 20, 2018 / If you want a free Stock Review on TSRO sign up now at www.wallstequities.com/registration. Markets served include medical, agricultural, environmental, and industrial.Ahead of today's trading session, WallStEquities.com observes Teligent Inc. (NASDAQ: TLGT), Tesaro Inc. (NASDAQ: TSRO), Vascular Biogenics Ltd (NASDAQ: VBLT), and VistaGen Therapeutics Inc. (NASDAQ: VTGN).
For 1/3 of epilepsy patients, drugs won't control their seizures. Surgery may be an option (curative for some patients) but figuring out on what part of the brain to operate may require major brain surgery first: costly and invasive. This kind of event could put a lot of eyeballs on NMTC, and the stock has room to run as it goes through its first price discovery period.
The additional coverage that has VTGN stock soaring today is from research firm Oppenheimer. This new coverage of Vistagen Therapeutics Inc comes from analyst Jay Olson. Olson started his coverage with an incredibly bullish price target of $6.00 and an “Outperform” rating.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Foot Locker, Inc. (NYSE: FL ) stock was trading higher ...
Shares of VistaGen Therapeutics Inc (NASDAQ: VTGN ) rocketed up over 40 percent to $1.36 in after-hours trading on Thursday — a mere fraction of the 500 percent upside implied by a late-day note from Oppenheimer. ...